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Available online 4 February 2016Purpose: Evaluating the cost-effectiveness of a ﬁrst-line smoking cessation drug using an electronic medical
record system is very important for deﬁning the best decision-making tree to use in the Brazilian National Health
System (SUS). This study aimed to evaluate the cost effectiveness of varenicline compared with bupropion and
nicotine replacement therapy (NRT) (gum and patches) in a smoking cessation program.
Methods:We included 940 patients admitted to a smoking cessation program. Smokers had access to medical
consultations and prescription of nicotine replacement therapies (NRT — patch and gum), bupropion, and
varenicline. Incremental cost-effectiveness ratios (ICERs) were estimated in the perspective of the Brazilian
Public Health System (SUS).
Results:We were able to show that the best cost-effectiveness for one participant to quit smoking was BRL R$
1.546,40 with varenicline plus bupropion BRL R$ 1.650,00 with varenicline alone; BRL R$ 1.971,32 with
bupropion plus gum; BRL R$ 2.413,81 with bupropion plus NRT; and BRL R$ 2.414,26 with NRT alone.
Conclusion: Treatment with varenicline showed to be dominant and cost saving compared to NRT and/or
bupropion.







Smoking can be described as an epidemic that kills 5.4 million
people every year, primarily due to lung cancer and cardiovascular
disease. This makes smoking a key modiﬁable risk factor for increased
morbidity and mortality [1], which generates a substantial burden to
the economyof countries aswell as loss of productivity due tomorbidity
and early death [2].
The use of medications is an additional resource in smoking
cessation, being particularly useful when behavioral interventions are
ineffective, usually due to a high level of nicotine dependence [3].
Nonetheless, the use of medications adds considerable cost to the
overall expenditure of smoking cessation programs. Cost-effectiveness
analyses have been marginally conducted to guide widespread use ofUniversity of Sao Paulo Medical
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en access article under the CC BY-NCdifferent smoking cessation treatments in developing countries. The
Brazilian National Health System (SUS) offers bupropion and nicotine
replacement therapy for free. Varenicline is not available for SUS pa-
tients. Evaluating the cost-effectiveness of a ﬁrst-line smoking
cessation drug using an electronic medical record system is very impor-
tant for deﬁning the best decision-making tree to use in the Brazilian
National Health System (SUS) [4].2. Study aims
This study aimed to evaluate the cost effectiveness of varenicline
compared with bupropion and nicotine replacement therapy (NRT)
(gum and patches) in a smoking cessation program at the Heart
Institute (InCor), which is part of the University of São Paulo's medical
complex and offers treatment for SUS patients and private patients.
The decision to choose varenicline as the reference treatment was
based on the superior efﬁcacy of this drug compared to that of
bupropion or NRT.
The secondary aim was to determine the incremental cost of using
multiple medications to identify the treatment that offers the greatest
cost savings.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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We conducted an outcome research from patients treated in the
smoking cessation program at InCor, using the Program of Assistance
to Smokers (Programa de Assistência do Fumante—PAFWEB) database
available at http://www.pafweb.com.br. Data were collected between
2008 and 2011, and the Ethics Committee of the Hospital das Clínicas,
University of São Paulo Medical School (CAPpesq) approved the study.
Inclusion criteria were smokers, over 18 years of age, undergoing
smoking cessation treatmentwith aﬁrst-linemedication, and consenting
to have personal data analyzed. Individuals who did notmatch the inclu-
sion criteria were excluded. First-line medications for smoking cessation
included in this study were nicotine replacement therapy (NRT) (either
gum or patch), bupropion, and varenicline.
Patients were divided into 5 groups: group 1 received varenicline
only, group 2 received both varenicline andbupropion, group 3 received
bupropion andNRT gum, group 4 received bupropion and NRT gum and
patches, and group 5 received NRT (gum and/or patch) alone.
NRT and bupropion were available for free for all patients in the
Brazilian National Health System (SUS). Varenicline is not available
for SUS patients yet, but we obtained free samples for some patients
from SUS (108 from 585 SUS patients received varenicline—18% of
this sample). We prescribed varenicline to the majority of private
patients (246 of 355 private patients—70% of this sample). The
study population was divided into groups according to the medica-
tion used. The patients whowished to begin smoking cessation treat-
ment received an individual medical approach and prescription for
smoking cessation drugs for at least 12 weeks. These drugs were
initiated as monotherapy according to the nicotine dependence
level of the patient; previous use of smoking cessation medication;
availability of medication, and contraindications. NRT was pre-
scribed preferentially to SUS patients, who were men who smoked
at least 20 cigarettes per day. Bupropion was prescribed to SUS
patients who smoked more than 20 cigarettes per day or women
who smoked at least 20 cigarettes per day. These study drugs could
be combined to help a patient achieve the smoke-free status or de-
crease withdrawal symptoms. For this study, varenicline was made
available for use by SUS patients. In this case, varenicline was used
in patients who failed to stop smoking in previous attempts with
NRT and/or bupropion, or who smoked one or more pack(s) of ciga-
rettes per day. Varenicline was the ﬁrst choice for private patients.
Our indication to start providing bupropion at 150 mg/day was if
the patient did not achieve complete abstinence 2 or 3 weeks after
starting varenicline, or if the patient achieved complete abstinence,
but experienced moderate or intense withdrawal symptoms.Table 1





SUS patients (n = 585) 81 (32.9) 27 (25.0)
Private patients (n = 355) 165 (67.1) 81 (75.0)
Age (years) 54 ± 11 51 ± 11
Gender, female (%) 54.1 56.5
Ethnicity, White (%) 89.5 86.6
Fagerstrom score 7.3 ± 2.5a 7.7 ± 2.5a
Hypertension (%) 36.6 34.3
Coronary artery disease (%) 12.2 12.0
Acute myocardial infarction (%) 12.2 9.3
Dyslipidemia (%) 32.9 37.0
Type 2 diabetes mellitus (%) 9.3 14.8
Depression (%) 23.8 26.9
Anxiety (%) 15.4 20.4
Obstructive pulmonary chronic disease (%) 14.6 23.1
Asthma (%) 2.8 3.7
Number of diagnosed diseases 2.2 ± 1.5a 2.0 ± 1.7a
Number of other medications 2.2 ± 2.6a 2.0 ± 3.1a
Different superscript letters mean values signiﬁcantly different (post-hoc test).The costs evaluated in this study refer to ﬁrst-line medications
used for smoking cessation in the Brazilian National Health System
and were veriﬁed using the Health Prices Bank (BPS). The effectiveness
of treatment was calculated separately for each of the ﬁve treat-
ment groups, by dividing the number of patients that successfully
quit smoking by the total number of patients in the group.
The cost-effectiveness was assessed through a comparison of all
treatment options: the incremental clinical beneﬁt (the cost per
patient treated) was obtained by dividing the cost of each treatment
by its effectiveness.
To estimate the costs and results of each treatment, we developed a
model in the form of a decision-making tree, representing the effective-
ness of each of the ﬁve treatment groups and the direct cost of themed-
ication. Initially, all patients were in the clinical condition of “smokers”
from this initial point, ﬁve branches represent each of the ﬁve treatment
groups. In each branch, two clinical outcomes are possible: “success”,
characterized by continuous abstinence for 52 weeks, or “failure”, in
which the patient remains as a smoker. Analyses for this study were
conducted using SPSS version 16 software.
4. Results
Five groups were identiﬁed based on drugs used: group 1 included
246 patients using only varenicline, group 2 included 108 patients
using both varenicline and bupropion, group 3 included 183 patients
using bupropion and NRT gum, group 4 included 101 patients using
bupropion and NRT gum and patches, group 5 included 302 patients
using NRT (gum and/or patch) alone.
Table 1 shows the demographic proﬁle of the study population by
treatment group. In total, 940 patients were followed for 52 weeks,
585 were patients from SUS and 355 were private patients. We
were able to compare success to the anti-smoking treatment
received between private and SUS patients. We did not ﬁnd a signif-
icant difference in success rates for the varenicline and varenicline
plus bupropion groups (p = 0.36 and p = 0.10, respectively, and
Private vs SUS).
Table 2 shows cost, effectiveness, and cost-effectiveness according to
drugs used. We found the lower values for cost-effectiveness in groups
1 and2 (varenicline aloneor combinedwith bupropion) comparedwith
groups 3, 4, and 5 (without varenicline).
In addition, results of the cost-effectiveness analysis comparing
different treatments are presented as incremental cost-effectiveness
ratios (ICER), i.e., the difference in the cost of two treatments divided
by the difference in their effectiveness. Using group 1 (varenicline
only) as the reference group, we observed the following values: BR$Bupropion plus gum
(n = 183)





145 (79.2) 81 (80.2) 251 (83.1)
38 (20.8) 20 (19.8) 51 (16.9)
53 ± 10 53 ± 10 54 ± 11 0.87
78.7 58.4 32.8 b0.01
59.4 62.8 67.9 b0.01
5.9 ± 2.3b,c 6.4 ± 2.8b 5.3 ± 2.5c b0.01
55.7 58.4 62.3 b0.01
21.9 26.7 29.5 b0.01
23.0 27.7 34.1 b0.01
49.7 49.5 55.3 b0.01
15.3 7.9 13.9 0.16
25.6 23.8 20.2 0.52
27.9 20.8 14.2 b0.01
21.9 20.8 20.2 0.24
3.3 2.0 4.0 0.88
2.9 ± 1.9b 2.7 ± 1.7b 3.2 ± 1.9b b0.01
4.0 ± 3.3b 4.3 ± 3.9b 4.5 ± 3.2b b0.01
Table 2
Cost, effectiveness, and cost-effectiveness according to treatment options.
Drug Effectiveness (%) Cost Cost-effectiveness
Varenicline 39.4 BR$ 650.10 BR$ 1650.00
Varenicline + bupropion 47.2 BR$ 729.90 BR$ 1546.40
Bupropion + gum 31.7 BR$ 624.91 BR$ 1971.32
Bupropion + NRT 39.6 BR$ 955.87 BR$ 2413.81
NRT 33.1 BR$ 799.12 BR$ 2414.26
3J. Scholz et al. / Clinical Trials and Regulatory Science in Cardiology 14 (2016) 1–32365.40 for NRT, BR$ 1528.85 for bupropion plus NRT, BR$ 327.14 for
bupropion plus gum, and BR$ 1023.08 for varenicline plus bupropion.
5. Discussion
The decision to select the varenicline group as the reference group
was considered based on the superior efﬁcacy of this drug compared
with bupropion [5] or with NRT [6].
The decision-making tree in this study indicates that the greatest
cost-effective values were observed in patients who used varenicline
or varenicline plus bupropion. In addition, it was an important ﬁnding
that the cost-effectiveness of varenicline alone was BR$ 1650.00, while
the cost-effectiveness of varenicline plus bupropion was BR$ 1546.40.
Both drug therapies had lower values than the alternatives (bupropion
and NRT gum, bupropion and NRT gum and/or patch, and NRT alone),
which cost BR$ 1971.32, BR$ 2413.81, and BR$ 2414.26, respectively.
In a previous study from our group, we showed a higher success rate
in the patient group using varenicline plus bupropion compared with
the patient group using varenicline as monotherapy [7].
Furthermore, another current randomized, placebo-controlled trial
also identiﬁed the superiority of co-administration compared to
varenicline as monotherapy in patients with a high dependency [8].
The incremental cost-effectiveness analysis found that varenicline
alone, compared to NRT alone, saved BR$ 2365.40, and compared to
bupropion associated with NRT that saved BR$ 327.14. The cost-
effectiveness of varenicline in association with bupropion was BR$
1023.08, and for bupropion associated with NRT, it was BR$ 1528.85.
Therefore, varenicline seems to be cost-effective regardless of whether
it is prescribed alone or in combination with bupropion.
This evidence aligns with study results from other continents.
A study conducted in Finland compared the effectiveness of varenicline,
bupropion, and no treatment over 12weeks, and found that varenicline
was the most effective and resulted in cost savings compared to
bupropion or no treatment [9]. Another study conducted in Greece
found that when comparing varenicline, bupropion, NRT and no treat-
ment, varenicline improved the chances of successful smoking cessation
and signiﬁcantly reduced the overall costs of smoking cessation treat-
ment in the health care system [10]. Other researchers also evaluated
the cost-effectiveness of varenicline compared to other medications
available for smoking cessation and concluded that varenicline was
considered cost-effective in South Korea [11].
In the United States, a study compared varenicline, bupropion with
NRT, and no treatment; results indicated that varenicline is a low-cost
ﬁrst-line medication alternative for smoking cessation [12]. Another
study concluded that, for each of the paying parties (health care system,
health insurance, and the patient), the use of varenicline substantially
reduced health care costs [13].
A study in four European countries compared the cost-effectiveness
of varenicline with that of NRT for smoking cessation in adults betweenthe ages of 18 and 75. Under a smoking cessation beneﬁts model
(BENESCO), the incremental cost of varenicline compared to NRT
went from EUR $54,522.00 to EUR $200,200.00, demonstrating that
varenicline was cost-effective for the health care system [14].The initial
cost of varenicline is offset by savings associated with less morbidity
and mortality due to diseases associated with smoking. Despite its
limitations, cost-effectiveness analyses are already available in
several countries, all of which support the use of varenicline for 12
to 24 weeks as a low-cost treatment option to assist smokers in
achieving successful cessation [15].
In conclusion, this study is an outcome research of real-world
observations; therefore, it has intrinsic limitations including the lack
of a controlled environment and randomization. Despite that, these re-
sults indicate that, in the clinical environment and under evaluation
criteria by an electronic medical records system, varenicline alone or
when co-administered had lower values of cost-effectiveness. Smoking
is a risk factor for several chronic diseases and is responsible for a myr-
iad of health problems that generate excessive health care expenses
(including treatments, medications, and hospitalizations); therefore,
efforts to control and reduce smoking such as treatment with
drugs are extremely important in assisting smokers to achieve
successful cessation.References
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